135 related articles for article (PubMed ID: 16258534)
1. Cure of multiple myeloma -- more hype, less reality.
Hari P; Pasquini MC; Vesole DH
Bone Marrow Transplant; 2006 Jan; 37(1):1-18. PubMed ID: 16258534
[TBL] [Abstract][Full Text] [Related]
2. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
3. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
Durie BG
Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
[TBL] [Abstract][Full Text] [Related]
4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
5. Cure of myeloma: hype or reality?
Fassas A; Shaughnessy J; Barlogie B
Bone Marrow Transplant; 2005 Feb; 35(3):215-24. PubMed ID: 15543196
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation in multiple myeloma.
Pant S; Copelan EA
Biol Blood Marrow Transplant; 2007 Aug; 13(8):877-85. PubMed ID: 17640590
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
8. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
11. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
12. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
13. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
16. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F
Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
Kennedy GA; Butler J; Morton J; Hill G; Western R; Cummings J; Allison R; Durrant S
Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
[TBL] [Abstract][Full Text] [Related]
18. Symptom burden after autologous stem cell transplantation for multiple myeloma.
Campagnaro E; Saliba R; Giralt S; Roden L; Mendoza F; Aleman A; Cleeland C; Weber D; Brown J; Anderson KO
Cancer; 2008 Apr; 112(7):1617-24. PubMed ID: 18260091
[TBL] [Abstract][Full Text] [Related]
19. Role of allogeneic stem cell transplantation in multiple myeloma.
Bruno B; Giaccone L; Sorasio R; Boccadoro M
Semin Hematol; 2009 Apr; 46(2):158-65. PubMed ID: 19389499
[TBL] [Abstract][Full Text] [Related]
20. The allogeneic dilemma.
Harousseau JL
Bone Marrow Transplant; 2007 Dec; 40(12):1123-8. PubMed ID: 17680016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]